LEADER 03425nam 2200661 450 001 9910825328503321 005 20230125223149.0 010 $a1-63157-215-6 035 $a(CKB)3710000000861760 035 $a(BEP)4690656 035 $a(OCoLC)959032804 035 $a(CaBNVSL)swl00407171 035 $a(Au-PeEL)EBL4690656 035 $a(CaPaEBR)ebr11267625 035 $a(CaONFJC)MIL955253 035 $a(OCoLC)959150193 035 $a(CaSebORM)9781631572159 035 $a(MiAaPQ)EBC4690656 035 $a(EXLCZ)993710000000861760 100 $a20170303d2017 fy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 10$aAttributes of project-friendly enterprises /$fVittal S. Anantatmula and Parviz F. Rad 205 $aFirst edition. 210 1$aNew York, New York (222 East 46th Street, New York, NY 10017) :$cBusiness Expert Press,$d2017. 215 $a1 online resource (xii, 188 pages) $cillustrations 225 1 $aPortfolio and project management collection,$x2156-8200 311 $a1-63157-214-8 320 $aIncludes bibliographical references (pages 183-185) and index. 327 $a1. Introduction -- 2. Project attributes -- 3. Proposal attributes -- 4. Portfolio attributes -- 5. Team attributes -- 6. Enterprise attributes -- Appendix -- Bibliography -- Index. 330 3 $aThe objective of any organization is to create value for its stockholders. Given that sophistication in project management will lead to efficiency in operations, which in turn leads to better profits, enlightened enterprises are sensitive to project management sophistication and the definitive way of measuring it and improving it. Although in many organizations, projects are initiated in isolation of each other, and based on ad hoc urgencies, sophisticated enterprises have a formalized, logical, and consistent, structure for organizing, and managing, their projects. Project management sophistication is the state of enterprise practices in which success of projects is predictable and that the definitive measure of project management success continually improves with time. Conducting a full assessment of the organizational project management sophistication is relatively time consuming and costly. Thus, many organizations have a need and desire for instruments that would provide a rough estimate of the project management maturity of the organization without a major expenditure of funds. This book includes instruments that should help in that regard. 410 0$aPortfolio and project management collection.$x2156-8200 606 $aProject management 610 $aattributes 610 $aportfolios 610 $aprojects 610 $aproject management 610 $aproject management maturity 610 $aproject management sophistication 610 $aproject teams 610 $aproject-friendly organizations and enterprises 610 $aproposals 610 $asophistication 610 $avital signs 615 0$aProject management. 676 $a658.404 700 $aAnantatmula$b Vittal S.$f1955-,$01637801 702 $aRad$b Parviz F.$f1942-, 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910825328503321 996 $aAttributes of project-friendly enterprises$94070778 997 $aUNINA LEADER 04547nam 22007575 450 001 9910300205503321 005 20231012162836.0 010 $a1-61779-962-9 010 $a9781617799617$bpaperback 010 $a9781617799624$bebook 024 7 $a10.1007/978-1-61779-962-4 035 $a(CKB)3710000000291262 035 $a(EBL)1968152 035 $a(OCoLC)908088833 035 $a(SSID)ssj0001386385 035 $a(PQKBManifestationID)11884011 035 $a(PQKBTitleCode)TC0001386385 035 $a(PQKBWorkID)11351550 035 $a(PQKB)10194282 035 $a(DE-He213)978-1-61779-962-4 035 $a(MiAaPQ)EBC1968152 035 $a(PPN)183097130 035 $a(iGPub)SPNA0031815 035 $a(EXLCZ)993710000000291262 100 $a20141119d2015 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aCardiac Drug Therapy /$fby M. Gabriel Khan 205 $a8th ed. 2015. 210 1$aLondon :$cHumana Press,$d[2015] 215 $a1 online resource (806 p.) 225 1 $aContemporary Cardiology,$x2196-8969 300 $aDescription based upon print version of record. 311 08$aprint version : 9781617799617 320 $aIncludes bibliographical references at the end of each chapters and indexes. 327 $aBeta-Blockers: The Cornerstone of Cardiac Drug Therapy -- Beta-Blocker Controversies -- Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers -- ACE Inhibitor Controversies -- Calcium Antagonists (Calcium Channel Blockers) -- Calcium Antagonist Controversies -- Diuretics -- Hypertension -- Hypertension Controversies -- Angina -- Acute Myocardial Infarction -- Heart Failure -- Heart Failure Controversies -- Management of Cardiac Arrhythmias -- Cardiac Arrest -- Management of Infective Endocarditis -- Dyslipidemias -- Endocrine Heart Diseases -- Antiplatelet Agents, Anticoagulants, Factor XA Inhibitors, Thrombin Inhibitors -- Cardiac Drugs During Pregnancy and Lactation -- Effects of Drug Interactions -- Hallmark Clinical Trials -- Management of Cardiomyopathies -- Newer Agents. 330 $aThis book is an essential guide to the medical treatment of the cardiac patient and presents core principles of cardiovascular therapeutics as well as drug recommendations. Major classes of drugs are featured, including beta-blockers, ACE inhibitors, calcium antagonists, diuretics, and antiplatelet agents and unique insights into the controversies surrounding the use of specific drugs are explored, with answers given to the question: do beta blockers and diuretics really cause diabetes? Properties, dosage, side effects, potential salutary benefits, and drawbacks on virtually all commercially available cardiac drugs are examined. This revised edition is thoroughly updated and addresses the entire spectrum of heart disorders, such as hypertension, angina, myocardial infarction, heart failure, arrhythmias, cardiac arrest, and dyslipidemias. New chapters include endocrine heart diseases, management of cardiomyopathies, and newer agents. In addition, topics such as cardiac drugs in pregnancy and lactation and drug interactions are covered. Cardiac Drug Therapy, Eighth Edition, is an authoritative and clinically relevant resource for cardiologists, cardiology fellows, and internists. 410 0$aContemporary Cardiology,$x2196-8969 606 $aCardiology 606 $aInternal medicine 606 $aGeneral practice (Medicine) 606 $aPharmacology 606 $aCardiology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33037 606 $aInternal Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/H33002 606 $aGeneral Practice / Family Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/H24003 606 $aPharmacology/Toxicology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21007 615 0$aCardiology. 615 0$aInternal medicine. 615 0$aGeneral practice (Medicine). 615 0$aPharmacology. 615 14$aCardiology. 615 24$aInternal Medicine. 615 24$aGeneral Practice / Family Medicine. 615 24$aPharmacology/Toxicology. 676 $a616.12061 700 $aKhan$b M. I. Gabriel$0789322 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910300205503321 996 $aCardiac Drug Therapy$91760497 997 $aUNINA